BFAI

BFAI
Clinical data
Other names	5,6-Benzofuranyl-2-aminoindane; 5,6-Benzofuranyl-2-aminoindan
Drug class	Selective serotonin releasing agent; Entactogen
ATC code	None;
Identifiers
	IUPAC name 6,7-dihydro-5H-cyclopenta[f][1]benzofuran-6-amine;
PubChem CID	162728212;
Chemical and physical data
Formula	C11H11NO
Molar mass	173.215 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(CC2=C1C=C3C=COC3=C2)N;
	InChI InChI=1S/C11H11NO/c12-10-4-8-3-7-1-2-13-11(7)6-9(8)5-10/h1-3,6,10H,4-5,12H2; Key:SYCRQDBZPIEBIR-UHFFFAOYSA-N;

BFAI (5,6-benzofuranyl-2-aminoindane) is a drug of the 2-aminoindane group that acts as a serotonin releasing agent (SSRA) and produces entactogen effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.^[1] The drug was patented by Tactogen in 2022.^[1]

References

^ ^a ^b WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc.

[WO2022032147A1-1] WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc.

[1]

BFAI

See also

References